Doripenem

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.

Also Known As:

2-(5-sulfamoylaminomethylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapen-2-em-3-carboxylic acid; S 4661; S-4661; S4661; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-

Networked: 214 relevant articles (28 outcomes, 59 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nicolau, David P: 11 articles (01/2016 - 07/2008)
2.	Redman, Rebecca: 11 articles (11/2015 - 01/2009)
3.	Kaniga, Koné: 9 articles (04/2013 - 06/2005)
4.	Cirillo, Iolanda: 6 articles (11/2015 - 03/2011)
5.	Friedland, Ian: 6 articles (05/2010 - 04/2008)
6.	Lee, Michael: 5 articles (04/2013 - 04/2008)
7.	Tang, Hung-Jen: 4 articles (04/2022 - 01/2016)
8.	Chastre, Jean: 4 articles (01/2016 - 04/2008)
9.	Crandon, Jared L: 4 articles (01/2016 - 10/2009)
10.	Vaccaro, Nicole: 4 articles (08/2015 - 03/2011)

Related Diseases

1.	Infections 05/01/2010 - "Doripenem and comparators were highly clinically effective in infections caused by Enterobacteriaceae, irrespective of their ESBL statuses. " 06/01/2011 - "These results suggest that doripenem treatment is effective against chronic airway infection with P. " 12/01/2011 - "In our limited sample size, doripenem was safe and effective against various types of infections in a general inpatient population with similar bacterial susceptibilities to other cabapenems. " 01/01/2020 - "Due to the differences between human and rabbit pleural thickness, doripenem's pleural penetration should be examined in infection models in animals with equal pleura thickness and clinical trials." 10/01/2012 - "An in vitro dilutional pharmacokinetic model of infection was used to study the pharmacodynamics of doripenem in terms of the ability to kill Pseudomonas aeruginosa or Acinetobacter baumannii and also changes in their population profiles. "
2.	Urinary Tract Infections (Urinary Tract Infection) 07/02/2019 - "For complicated urinary tract infection, doripenem was associated with higher success rate than comparators (OR, 1.89, 95% CI, 1.13-3.17, I2 = 0%). " 12/01/2009 - "Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. " 12/01/2010 - "Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis." 11/01/2015 - "Three multicenter, randomized, controlled studies evaluated doripenem in children 3 months to <18 years of age, with complicated intra-abdominal or urinary tract infections and bacterial pneumonia.In" 12/01/2010 - "Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies. "
3.	Intraabdominal Infections 09/01/2010 - "In conclusion, doripenem is a valuable addition to the options available for the empirical treatment of hospitalized patients with serious intraabdominal infections." 11/01/2008 - "These results should help to achieve a better understanding of the peritoneal pharmacodynamics of doripenem while also helping to rationalize and optimize the dosing regimen for intra-abdominal infections." 07/02/2019 - "Similar clinical success rates were noted between doripenem and comparators for pneumonia (OR, 0.84; 95% CI, 0.46-1.53, I2 = 72%) and for intra-abdominal infections (OR, 1.00; 95% CI, 0.57-1.72). " 12/01/2016 - "Doripenem is approved by the Food and Drug Administration for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections. " 09/21/2009 - "In 2007, the US Food and Drug Administration approved the use of doripenem for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. "
4.	Healthcare-Associated Pneumonia 07/11/2022 - "Doripenem in the Treatment of Patients with Nosocomial Pneumonia: A Meta-Analysis." 08/01/2013 - "A pharmacokinetic (PK) analysis of a 1-h intravenous (i.v.) dose of 500 mg doripenem in ten clinically ill, elderly patients with nosocomial pneumonia (NP) was conducted. " 08/01/2013 - "Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia." 01/01/2010 - "Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation." 12/01/2009 - "In nosocomial pneumonia, doripenem showed an interesting activity in P. "
5.	Ventilator-Associated Pneumonia 11/01/2012 - "The aim of this study was to assess the population pharmacokinetics and probabilities of target attainment (PTAs) of doripenem in patients with ventilator-associated pneumonia, comparing administration by 1-h and 4-h infusion. " 01/01/2010 - "Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators." 08/15/2009 - "The reduced medical resource use achieved with use of doripenem for treatment of ventilator-associated pneumonia may provide not only clinical benefits to patients but also economic benefits to hospitals and health care systems." 08/15/2009 - "The topics addressed include antimicrobial resistance and the available therapeutic options against gram-negative pathogens, the in vitro activity of doripenem, the efficacy and safety of intravenous infusion of doripenem, and the clinical and economic consequences of ventilator-associated pneumonia. " 01/01/2020 - "Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia."

Related Drugs and Biologics

1.	Meropenem (Merrem)
2.	Carbapenems (Carbapenem Antibiotics)
3.	Imipenem
4.	Ertapenem (Invanz)
5.	Levofloxacin (Levaquin)
6.	Tazobactam Drug Combination Piperacillin (Zosyn)
7.	ceftazidime drug combination avibactam
8.	Colistin (Coly-Mycin)
9.	Vancomycin
10.	Anti-Infective Agents (Microbicides)

Related Therapies and Procedures

1.	Therapeutics
2.	Continuous Renal Replacement Therapy
3.	Hemodiafiltration
4.	Intravenous Infusions
5.	Intravenous Administration